ANTX

AN2 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.

Wall Street analysts forecast ANTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANTX is 1.67 USD with a low forecast of 1.00 USD and a high forecast of 2.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

AN2 Therapeutics Inc revenue for the last quarter amounts to -11.54M USD, decreased -36.94 % YoY.

AN2 Therapeutics Inc. EPS for the last quarter amounts to -10624000.00 USD, decreased -39.61 % YoY.

AN2 Therapeutics Inc (ANTX) has 22 emplpoyees as of December 15 2025.

Today ANTX has the market capitalization of 66.52M USD.